Dalbavancin: Difference between revisions
Elcatracho (talk | contribs) |
Elcatracho (talk | contribs) |
||
| (10 intermediate revisions by the same user not shown) | |||
| Line 19: | Line 19: | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
* | *CrCl less than 30 mL/min and not receiving hemodialysis: Single-dose regimen, 1125 mg IV infusion; 2-dose regimen, 750 mg IV infusion followed by 375 mg IV infusion 1 week later<ref>Product Information: DALVANCE(R) intravenous injection, dalbavancin intravenous injection. Durata Therapeutics Inc. (per manufacturer), Parsippany, NJ, 2016.</ref> | ||
* | *No adjustment necessary if on [[hemodialysis]] | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
* | *Hepatic impairment, mild (Child-Pugh class A): No adjustment necessary | ||
* | *Hepatic impairment, moderate to severe (Child-Pugh class B or C): Appropriate dosage has not been determined | ||
==Contraindications== | ==Contraindications== | ||
| Line 33: | Line 33: | ||
*Gastrointestinal: [[Clostridium difficile]] colitis (<2%), Clostridium difficile diarrhea, [[GI bleed]] (<2% ) | *Gastrointestinal: [[Clostridium difficile]] colitis (<2%), Clostridium difficile diarrhea, [[GI bleed]] (<2% ) | ||
*Hepatic: ALT/SGPT level raised (0.8%) | *Hepatic: ALT/SGPT level raised (0.8%) | ||
*Immunologic: Hypersensitivity reaction | |||
===Common=== | ===Common=== | ||
*Gastrointestinal: [[Diarrhea]] (Up to 4.4%), Nausea (Up to 5.5%) | |||
*Neurologic: Headache (Up to 4.7%) | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 8.5 days | ||
*Metabolism: | *Metabolism: | ||
*Excretion: | *Excretion: Fecal (20%), Renal (33%) | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Semisynthetic lipoglycopeptide antibacterial agent that inhibits cell wall peptidoglycan cross-linking | |||
*Same MOA and class as [[vancomycin]] | |||
==Comments== | ==Comments== | ||
| Line 51: | Line 52: | ||
==See Also== | ==See Also== | ||
*[[Antibiotics (Main)]] | |||
*[[Antibiotics by diagnosis]] | |||
*[[Antibiotics by organism]] | |||
==References== | ==References== | ||
Latest revision as of 20:09, 7 April 2021
Administration
- Type: Antibiotic
- Dosage Forms: 500 mg/vial; reconstituted concentration 20 mg/ml
- Routes of Administration: Intravenous
- Common Trade Names: Dalvance
Adult Dosing
- 1500 mg as single dose or 1000 mg then 500 mg one week later; infuse over 30 minutes
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Special Populations
Pregnancy Rating
- Maternal risk cannot be ruled out
Lactation risk
- Fetal risk cannot be ruled out
Renal Dosing
- CrCl less than 30 mL/min and not receiving hemodialysis: Single-dose regimen, 1125 mg IV infusion; 2-dose regimen, 750 mg IV infusion followed by 375 mg IV infusion 1 week later[1]
- No adjustment necessary if on hemodialysis
Hepatic Dosing
- Hepatic impairment, mild (Child-Pugh class A): No adjustment necessary
- Hepatic impairment, moderate to severe (Child-Pugh class B or C): Appropriate dosage has not been determined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Gastrointestinal: Clostridium difficile colitis (<2%), Clostridium difficile diarrhea, GI bleed (<2% )
- Hepatic: ALT/SGPT level raised (0.8%)
- Immunologic: Hypersensitivity reaction
Common
- Gastrointestinal: Diarrhea (Up to 4.4%), Nausea (Up to 5.5%)
- Neurologic: Headache (Up to 4.7%)
Pharmacology
- Half-life: 8.5 days
- Metabolism:
- Excretion: Fecal (20%), Renal (33%)
Mechanism of Action
- Semisynthetic lipoglycopeptide antibacterial agent that inhibits cell wall peptidoglycan cross-linking
- Same MOA and class as vancomycin
Comments
See Also
References
- ↑ Product Information: DALVANCE(R) intravenous injection, dalbavancin intravenous injection. Durata Therapeutics Inc. (per manufacturer), Parsippany, NJ, 2016.